Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

  • End date
    Sep 24, 2023
  • participants needed
  • sponsor
    Istituto Clinico Humanitas
Updated on 24 January 2021
antiviral therapy
neutrophil count
radiofrequency ablation
antiviral drugs


This is an open-label, single-center, Phase II trial designed to estimate in terms of PFS the efficacy of cabozantinib, given as second- or third- line treatment in HCC patients that progress on or are intolerant to immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 antibodies.


Subjects who meet all study eligibility criteria will take tablets containing 60 mg of cabozantinib once daily orally. Required dose reductions will be in decrements of 20 mg cabozantinib (maximum two dose reductions).

Subjects will receive study treatment as long as they continue to experience clinical benefit in the opinion of the investigator or until there is unacceptable toxicity.

Primary objective of this study is to evaluate the efficacy of cabozantinib, given as secondor third-line treatment in HCC patients that progress on or are intolerant to immune checkpoint inhibitors.

Secondary objectives for this study are as follows:

  • To evaluate the activity of cabozantinib, in terms of ORR (CR+PR) as per RECIST 1.1, duration of response, time to treatment failure (TTF), time to progression (TTP), and OS
  • To evaluate the safety and tolerability of cabozantinib

Condition HEPATOCELLULAR CARCINOMA, liver cell carcinoma
Treatment Cabozantinib 60 MG
Clinical Study IdentifierNCT04435977
SponsorIstituto Clinico Humanitas
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Histological or cytological diagnosis of HCC (results of a previous biopsy will be accepted)
A baseline tumor tissue (newly obtained) available at screening is optional. Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines and requirements for such procedure. Biopsy cannot be performed less than ten days before treatment start
The subject has disease that is not amenable to a locoregional treatment approach (eg, transplant, surgery, radiofrequency ablation, TACE)
Patients must have documented disease progression following at least 1 and no more than 2 prior systemic regimens for advanced disease (nonresectable or metastatic), the last of which includes immune checkpoint inhibitors. Alternatively, eligible patients may have experienced an immune-related, requiring treatment discontinuation
Recovery to Grade 1 from toxicities related to any prior treatments, unless the adverse events are clinically not significant and/or stable on supportive therapy
Age 18 years old on the day of consent
ECOG performance status of 0 or 1 (See Appendix V)
Adequate hematologic function, based upon meeting the following laboratory criteria within 7 days before treatment beginning
a. absolute neutrophil count (ANC) 1200/mm3 ( 1.2 x 109/L)
b. platelets 60,000/mm3 ( 60 x 109/L)
c. hemoglobin 8 g/dL ( 80 g/L)
Adequate renal function, based upon meeting the following laboratory criteria: serum creatinine 1.5 upper limit of normal or calculated creatinine clearance 40 mL/min (using the Cockroft-Gault equation: (140 - age) x weight (kg)/(serum creatinine 72 [mg/dL]) for males. (For females multiply by 0.85)
Child-Pugh Score of A (See Appendix IV)
Total bilirubin 2 mg/dL within 7 days before treatment start
Serum albumin 2.8 g/dL ( 28 g/L) within 7 days before treatment start
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 5.0 upper limit of normal (ULN)
Antiviral therapy per local standard of care if active hepatitis B (HBV) infection
Capable of understanding and complying with the protocol requirements and signed informed consent
Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment
Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression, low body weight, or other reasons

Exclusion Criteria

Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma
Child-Pugh score of B or C
Any type of anticancer agent (including investigational) within 2 weeks before treatment start
Radiation therapy within 4 weeks (2 weeks for radiation for bone metastases) or radionuclide treatment (eg, I-131 or Y-90) within 6 weeks of treatment start. Subject is excluded if there are any clinically relevant ongoing complications from prior radiation therapy
Prior cabozantinib treatment
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months before treatment start. Eligible subjects must be without corticosteroid treatment at the time of treatment start
Concomitant anticoagulation, at therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, low molecular weight heparin (LMWH), thrombin or coagulation factor X (FXa) inhibitors, or antiplatelet agents (eg, clopidogrel). Low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin ( 1 mg/day), and low-dose LMWH are permitted
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions
a. Cardiovascular disorders including
i. Symptomatic congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmias
ii. Uncontrolled hypertension defined as sustained BP > 150 mm Hg systolic, or > 100 mm Hg diastolic despite optimal antihypertensive treatment
iii. Stroke (including TIA), myocardial infarction, or other ischemic event within 6 months before treatment start
iv. Thromboembolic event within 3 months before treatment start. Subjects with thromboses of portal/hepatic vasculature attributed to underlying liver disease and/or liver tumor are eligible
b. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation
i. Tumors invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction
ii. Abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess within 6 months before treatment start
Note: Complete healing of an intra-abdominal abscess must be confirmed prior to treatment start
c. Major surgery within 2 months before treatment start. Complete healing from major surgery must have occurred 1 month before treatment start. Complete healing from minor surgery (eg, simple excision, tooth extraction) must have occurred at least 7 days before treatment start. Subjects with clinically relevant complications from prior surgery are not eligible
d. Cavitating pulmonary lesion(s) or endobronchial disease
e. Lesion invading a major blood vessel including, but not limited to: inferior vena cava, pulmonary artery, or aorta. Subjects with lesions invading the portal vasculature are eligible
f. Clinically significant bleeding risk including the following within 3 months of treatment start: hematuria, hematemesis, hemoptysis of >0.5 teaspoon (>2.5 mL) of red blood, or other signs indicative of pulmonary hemorrhage, or history of other significant bleeding if not due to reversible external factors
g. Other clinically significant disorders such as
i. Active infection requiring systemic treatment, known infection with human immunodeficiency virus (HIV), or known acquired immunodeficiency syndrome (AIDS)-related illness. Subjects with active hepatitis virus infection controlled with antiviral therapy are eligible
ii. Serious non-healing wound/ulcer/bone fracture
iii. Malabsorption syndrome
iv. Uncompensated/symptomatic hypothyroidism
v. Requirement for hemodialysis or peritoneal dialysis
vi. History of solid organ transplantation
vii. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding. Subjects treated with adequate endoscopic therapy (according to institutional standards)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note